2-羟基环戊烷羧酸乙酯 | 54972-10-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: 2-羟基环戊烷羧酸乙酯
• 英文名称: 2-hydroxycyclopentanecarboxylic acid ethyl ester
• 英文别名: ethyl 2-hydroxycyclopentanecarboxylate；(1S,2R)-ethyl 2-hydroxycyclopentanecarboxylate；1-ethoxycarbonyl-2-hydroxycyclopentane；2-hydroxy-cyclopentanecarboxylic acid ethyl ester；2-Hydroxy-cyclopentancarbonsaeure-aethylester；rac-(Z)-2-Hydroxy-cyclopentane-carboxylic acid ethyl ester；ethyl 2-hydroxycyclopentane-1-carboxylate
• CAS: 54972-10-0
• 化学式: C₈H₁₄O₃
• mdl: MFCD02093827
• 分子量: 158.197
• InChiKey: IIFIGGNBUOZGAB-UHFFFAOYSA-N

物化性质

• 沸点：
  61 °C(Press: 0.5 Torr)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  应存放在室温、密封且干燥的环境中。

反应信息

• 作为反应物：
  描述：

  2-羟基环戊烷羧酸乙酯 在 氢氧化钾 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 27.0h， 生成 1-环戊烯羧酸
  参考文献：
  名称：

  Structure-Activity Relationships of Unsaturated Analogs of Valproic Acid

  摘要：

  The principal metabolite of valproic acid (VPA), 2-ene VPA, appears to share most of VPA's pharmacological and therapeutic properties while lacking its hepatotoxicity and teratogenicity, thus making it a useful lead compound for the development of safer antiepileptic drugs. Analogues of 2-ene VPA were evaluated for anticonvulsant activity in mice using the subcutaneous pentylenetetrazole test. Cyclooctylideneacetic acid exhibited a potency markedly exceeding that of VPA itself with only modest levels of sedation. Potency, as either ED(50) or brain concentration, was highly correlated (r > 0.85) with volume and lipophilicity rather than with one of the shape parameters calculated by molecular modeling techniques, arguing against the existence of a specific receptor site. Instead, a role for the plasma membrane in mediating the anticonvulsant effect is suggested.

  DOI：

  10.1021/jm00017a024
• 作为产物：
  描述：

  己二酸二乙酯 在 sodium amalgam 、 乙醇 、 水 作用下， 生成 2-羟基环戊烷羧酸乙酯
  参考文献：
  名称：

  Dieckmann, Justus Liebigs Annalen der Chemie, 1901, vol. 317, p. 104

  摘要：

  DOI：

文献信息

• Chiral Diphosphonites as Ligands in the Ruthenium-Catalyzed Enantioselective Reduction of Ketones, B-Ketoesters and Ketimines
  申请人：Reetz Manfred T.

  公开号：US20080255355A1

  公开（公告）日：2008-10-16

  Chiral ruthenium complexes are disclosed, obtained by reaction of a ruthenium salt with a chiral diphosphonite. Chiral diols with the general structure given in scheme 1 are preferably used as chiral diphosphonites. Said ruthenium complexes can be simply and economically obtained and provide high enantioselectivity on reduction of ketones, β-ketoesters and ketimines.

  手性钌配合物是通过钌盐与手性二膦酯反应得到的。具有方案1中给出的一般结构的手性二醇通常用作手性二膦酯。这些钌配合物可以简单经济地获得，并在酮，β-酮酯和酮亚胺还原反应中提供高对映选择性。
• Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators
  申请人：——

  公开号：US20030225283A1

  公开（公告）日：2003-12-04

  2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

  2,3-二取代N-杂环丙酰胺，其中2-位置的取代物是取代苯基，3-位置的取代物是极性环，这些丙酰胺是葡萄糖激酶激活剂，可增加胰岛素分泌，用于治疗2型糖尿病。
• [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222483A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁超载状态，如地中海贫血、镰状细胞病和血色病，以及肾损伤。
• Reductions of cyclic β-keto esters by individual Saccharomyces cerevisiae dehydrogenases and a chemo-enzymatic route to (1R,2S)-2-methyl-1-cyclohexanol
  作者：Santosh Kumar Padhi、Iwona A. Kaluzna、Didier Buisson、Robert Azerad、Jon D. Stewart

  DOI：10.1016/j.tetasy.2007.08.010

  日期：2007.9

  Twenty purified dehydrogenases cloned from bakers’ yeast (Saccharomyces cerevisiae) and expressed as fusion proteins with glutathione (S)-transferase were tested for their ability to reduce three homologous cyclic β-keto esters. The majority of dehydrogenases reduced ethyl 2-oxo-cyclopentanecarboxylate, yielding a pair of diastereomeric alcohols with consistent (1R)-stereochemistry. Ethyl 2-oxo-cy

  测试了从面包酵母（Saccharomyces cerevisiae）克隆并表达为与谷胱甘肽（S）-转移酶融合蛋白的20种纯化的脱氢酶还原三种同源环状β-酮酯的能力。大多数脱氢酶还原2-氧代-环戊烷甲酸乙酯，产生一对具有一致的（1 R）-立体化学的非对映异构醇。2-氧代-环己烷甲酸乙酯的还原仅提供顺式-醇对映体。集合中的两种酶均接受2-氧代-环庚烷甲酸乙酯，两者均主要产生顺式-（1 R，2 S）-醇。大肠杆菌过量表达YDL124w基因的细胞用于动态动力学拆分2-氧代-环己烷甲酸乙酯，以生产化学合成重要的手性化合物（1 R，2 S）-2-甲基-1-环己醇的关键中间体积木。
• QUINOXALINE COMPOUND
  申请人：Kaizawa Hiroyuki

  公开号：US20110319385A1

  公开（公告）日：2011-12-29

  [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

  提供一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分。现有发明人研究了一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分，因此，发现咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，从而完成了本发明。本发明的咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，可用作预防和/或治疗储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂。